WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has been named to the 2024 Dow Jones Sustainability Indices (DJSI) for the second consecutive year. The company's commitment to sustainable development and responsible business practices has earned it top scores in the DJSI World and DJSI Emerging Markets Index, placing it among the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented on the achievement: "We are honored to be included in the DJSI list for the second consecutive year. This recognition reflects our continuous commitment to enhancing sustainability capabilities and driving long-term value for our stakeholders. As a global leader in Green CRDMO, we remain dedicated to delivering excellence in ESG performance while enabling global partners with end-to-end solutions driven by innovation."

Over the past several years, WuXi Biologics has earned numerous recognitions for its significant progress in pursuing sustainable development. The company was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its global leading green biologics solutions. It also received an AAA rating from MSCI ESG Ratings for two consecutive years, a Platinum Medal from EcoVadis, and was recognized as an Industry and Regional Top-Rated Company by Sustainalytics. Additionally, WuXi Biologics was named to the CDP Water Security 'A list' and awarded an 'A-' CDP Climate Change score, selected as a Constituent of the FTSE4Good Index Series, and included in the Hang Seng ESG 50 Index.



WuXi Biologics' commitment to sustainability is evident in its continuous improvement initiatives, such as the WuXi Biologics Business Management System (WBS), which aims to enhance operational efficiency, reduce waste, and improve overall ESG performance. The company's focus on sustainability has not only contributed to its financial performance but has also enhanced its reputation, improved risk management, and attracted top talent.

As the global biologics industry continues to grow, WuXi Biologics' commitment to sustainable development will remain a critical factor in its long-term success. By integrating ESG principles into its business strategy, the company is well-positioned to contribute to the achievement of the UN Sustainable Development Goals (SDGs) and foster a more sustainable and inclusive future for all stakeholders.